Risk of Pneumonia in Intubated Patients in Emergency Situations (PNEUMIOT)

February 23, 2026 updated by: University Hospital, Clermont-Ferrand

Orotracheal intubation in emergency medicine is a vital procedure for ensuring adequate oxygenation and ventilation in patients with respiratory distress or in shock. However, this procedure exposes patients to complications such as pneumonia. In the matter of fact, the urgency of the procedure means that it is not possible to wait until the patient's stomach is empty. Pneumonia significantly increase patient morbidity and mortality. Therapeutic management must be early and appropriate to improve the patient's prognosis.

The aim of this study is to compare the rate of pneumonia occurring in patients intubated in emergency situations with that in patients intubated in non-emergency situations in all 2024. Health data will only collected from patient's medical records.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

600

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Aurillac, France, 15000
        • CH Aurillac
        • Contact:
        • Principal Investigator:
          • Jonathan DUCHENNE
      • Clermont-Ferrand, France
      • Le Puy-en-Velay, France, 43000
        • CH du Puy en Velay
        • Contact:
        • Principal Investigator:
          • Adrien ROBERT
        • Sub-Investigator:
          • Angelo Giordano KWAKYE AGYEMANG
      • Montluçon, France, 03100
        • CH de Montluçon
        • Contact:
        • Principal Investigator:
          • Sébastien LOISEAU
      • Moulins, France, 03000
      • Vichy, France, 03200
        • CH de Vichy
        • Contact:
        • Principal Investigator:
          • Gaël GIBOT

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Study population is patient intubated in emergency situation and patients intubated in non-emergency situation following to the admission of intensive care in 2024.

Description

Inclusion Criteria:

  • Adult man or woman
  • Emergency and non-emergency intubated patient in 2024
  • Patient hospitalized in intensive care following intubation in 2024

Exclusion Criteria:

  • Patient under guardianship, curatorship or safeguard of justice
  • Pregnant woman
  • Refusal to participate

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intubated patients in emergency situations
Health data will be collected only with medical's record of intubated patients in emergency situation in 2024.
Intubated patients in non emergency situations
Health data will be collected only with medical's record of intubated patients in non emergency situation in 2024.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pneumonia rate in 48 hours after the start of orotracheal intubation.
Time Frame: Hour 48
Rate of pneumonia occuring within 48 hours of the start of orotracheal intubation.
Hour 48

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pneumonia rate occuring 48 hours after the start of orotracheal intubation.
Time Frame: 3 months
Rate of pneumonia occuring more than 48 hours after the start of orotracheal intubation.
3 months
Duration of mechanical ventilation
Time Frame: Up to the end of mechanical ventilation (assessed up to 1 month)
Duration of mechanical ventilation
Up to the end of mechanical ventilation (assessed up to 1 month)
Duration of stay in intensive care
Time Frame: Up to intensive care discharge (assessed up to 1 month)
Duration of stay in intensive care
Up to intensive care discharge (assessed up to 1 month)
Duration of hospital stay
Time Frame: Up to hospital discharge (assessed up to 3 months)
Duration of hospital stay
Up to hospital discharge (assessed up to 3 months)
Mortality rate
Time Frame: Inclusion + 1 year
Mortality rate
Inclusion + 1 year
Type of bacteria responsible for pneumonia
Time Frame: The day of the diagnosis of pneumonia (assessed up to 1 month)
The bacterial species responsible for pneumonia will be identified using biological samples (blood, urine, bronchial secretions) taken from patients in both groups. The identification of bacterial species will be carried out in the laboratory.
The day of the diagnosis of pneumonia (assessed up to 1 month)
Type of antibiotic administered for pneumonia
Time Frame: Up to the last day of antibiotic treatment (assessed up to 3 months)
Type of antibiotic administered for pneumonia in each group
Up to the last day of antibiotic treatment (assessed up to 3 months)
Antibiotic doses administered for pneumonia
Time Frame: Up to the last day of antibiotic treatment (assessed up to 3 months)
Comparison of antibiotic doses in g or mg administered in each group
Up to the last day of antibiotic treatment (assessed up to 3 months)
Duration of antibiotic treament for pneumonia
Time Frame: Up to the last day of antibiotic treatment (assessed up to 3 months)
Duration of antibiotic treament for pneumonia in each group
Up to the last day of antibiotic treatment (assessed up to 3 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Clermont-Ferrand

Investigators

  • Principal Investigator: Jean-Baptiste BOUILLON-MINOIS, University Hospital, Clermont-Ferrand

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 9, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

February 6, 2026

First Submitted That Met QC Criteria

February 23, 2026

First Posted (Actual)

February 27, 2026

Study Record Updates

Last Update Posted (Actual)

February 27, 2026

Last Update Submitted That Met QC Criteria

February 23, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025_BOUILLON MINOIS_Pneumiot

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pneumonia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe